Biotech Values

[DewDiligence]

SBOT reverse-merges into Edesa Biotech:

https://finance.yahoo.com/news/stellar-biotechnologies-edesa-biotech-sign-140000195.html

Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in immunotherapy and immuno-oncology development pipelines, has executed a share exchange agreement with privately-held Edesa Biotech Inc…to create a company focused on the development of innovative therapeutics for dermatological and gastrointestinal indications with clear unmet medical needs.

…Following the closing, current Stellar shareholders are expected to own approximately 10%, and the current shareholders of Edesa are expected to own approximately 90%, of the combined company on a fully-diluted basis…

…Following closing, Stellar intends to develop a plan for the disposition of Stellar's operations, which is expected to include the wind down or spin-off of Stellar's legacy business.

IOW, SBOT’s 10% stake in the post-merger company derives solely from its Nasdaq listing.